However, pain on swallowing, and vomiting were significantly more common in patients with CD4 <350 cells/μL than in controls. The authors conclude that the relatively low incidence of significant GI symptoms in HIV-infected patients may reflect the changing manifestations of HIV infection due to the success of antiretroviral therapy.
However, although the incidence of certain GI symptoms such as dysphagia and weight loss in the Jamaican population was similar to the incidence of GI symptoms reported in previous studies [10] , it was surprising that 35% of control patients had weight loss. Indeed, this present study has several limitations. Firstly, the weight loss as reported in this study was subjective and thus the estimated incidence may be inaccurate. Similarly, the subjective reporting of other GI symptoms such as belching and nausea may also explain why these symptoms were more common in the control patients. Secondly, the used questionnaire did not seek to determine if weight loss was intentional. Thirdly, the number of patients and controls was relatively small. Finally, the sample of HIV-infected patients represented only the ambulatory patients and was not entirely representative of the general population of HIV-infected patients. It would also be of interest to look at the possible association of specific antiretrovirals with the incidence of GI symptoms, similarly to previous studies [5, 10] .
In conclusion, improved symptom recognition of GI symptoms in HIV patients should be an essential component of patient care worldwide and an astute clinical acumen is often required to avoid subjective interpretation of certain GI symptoms.
